Experience with flutamide in previously untreated patients with advanced prostatic cancer.
Twenty-one patients with advanced prostatic adenocarcinoma previously untreated with conventional endocrine therapy were treated with an oral non-steroidal antiandrogen, flutamide. There were 19 favorable responders, 1 failure and 1 equivocal response. Flutamide seems to be a safe antiandrogen, which is effective in the management of previously untreated patients with advanced prostatic carcinoma.